AtriCure Reports First Quarter 2026 Financial Results
AtriCure, Inc. announced its first quarter 2026 financial results, emphasizing the durability of its growth model and increased adoption of its innovative products, as stated by CEO Michael Carrel.
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2026 financial results. “Our first quarter results reflect the durability of AtriCure’s growth model, fueled by disciplined execution and increased adoption of our innovative products,” said Michael Carrel, President and Chief Executive Officer